2023 Q3 Form 10-Q Financial Statement
#000155905323000026 Filed on August 03, 2023
Income Statement
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q4 |
|---|---|---|---|
| Revenue | $84.87M | $4.019M | $49.92M |
| YoY Change | 5494.33% | 206.33% | 4159.64% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $16.60M | $14.51M | $13.12M |
| YoY Change | 38.46% | 12.04% | 7.52% |
| % of Gross Profit | |||
| Research & Development | $57.91M | $56.01M | $36.87M |
| YoY Change | 45.29% | 77.42% | 67.15% |
| % of Gross Profit | |||
| Depreciation & Amortization | $200.0K | $200.0K | $196.0K |
| YoY Change | 0.0% | 0.0% | -18.33% |
| % of Gross Profit | |||
| Operating Expenses | $74.56M | $70.52M | $50.00M |
| YoY Change | 43.8% | 58.4% | 45.91% |
| Operating Profit | $10.31M | -$66.50M | |
| YoY Change | -120.48% | 53.91% | |
| Interest Expense | $8.500M | $7.700M | $3.744M |
| YoY Change | 344.33% | 1105.01% | 31100.0% |
| % of Operating Profit | 82.46% | ||
| Other Income/Expense, Net | $8.507M | $7.603M | -$327.0K |
| YoY Change | 344.23% | 1093.56% | 1943.75% |
| Pretax Income | $18.82M | -$58.90M | $3.345M |
| YoY Change | -138.86% | 38.36% | -110.11% |
| Income Tax | -$3.100M | -$4.300M | -$3.004M |
| % Of Pretax Income | -16.48% | -89.81% | |
| Net Earnings | $21.91M | -$54.60M | $6.349M |
| YoY Change | -147.87% | 32.37% | -119.14% |
| Net Earnings / Revenue | 25.81% | -1358.42% | 12.72% |
| Basic Earnings Per Share | $0.41 | -$1.03 | |
| Diluted Earnings Per Share | $0.38 | -$1.03 | $0.13 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 53.54M shares | 52.75M shares | 48.38M shares |
| Diluted Shares Outstanding | 58.00M shares | 53.12M shares |
Balance Sheet
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $670.9M | $659.1M | $710.4M |
| YoY Change | 35.36% | 29.54% | 22.68% |
| Cash & Equivalents | $670.9M | $659.1M | $710.4M |
| Short-Term Investments | |||
| Other Short-Term Assets | $14.50M | $17.47M | $8.692M |
| YoY Change | -49.89% | 39.76% | 52.09% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $5.159M | $524.0K | $0.00 |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $690.6M | $677.1M | $719.1M |
| YoY Change | 31.65% | 29.89% | 22.96% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.433M | $2.170M | $1.731M |
| YoY Change | 21.83% | 16.6% | -13.97% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $10.48M | $11.27M | $10.51M |
| YoY Change | 179.64% | 197.75% | 425.91% |
| Total Long-Term Assets | $56.32M | $43.55M | $38.94M |
| YoY Change | 88.49% | 53.9% | 58.56% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $690.6M | $677.1M | $719.1M |
| Total Long-Term Assets | $56.32M | $43.55M | $38.94M |
| Total Assets | $746.9M | $720.6M | $758.0M |
| YoY Change | 34.72% | 31.13% | 24.4% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $19.46M | $13.85M | $9.270M |
| YoY Change | 98.79% | 83.43% | 151.15% |
| Accrued Expenses | $30.50M | $30.65M | $28.33M |
| YoY Change | 2.45% | 43.25% | 35.31% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $53.37M | $71.57M | $50.15M |
| YoY Change | 5.48% | 78.44% | 49.91% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $0.00 | $0.00 | $553.0K |
| YoY Change | -100.0% | -100.0% | 0.0% |
| Total Long-Term Liabilities | $76.32M | $67.41M | $85.85M |
| YoY Change | -23.06% | -34.04% | -21.87% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $53.37M | $71.57M | $50.15M |
| Total Long-Term Liabilities | $76.32M | $67.41M | $85.85M |
| Total Liabilities | $129.7M | $139.0M | $136.0M |
| YoY Change | -13.42% | -2.33% | -5.11% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$912.6M | -$934.5M | -$833.0M |
| YoY Change | 8.72% | 17.75% | 16.33% |
| Common Stock | $536.0K | $535.0K | $521.0K |
| YoY Change | 11.9% | 14.32% | 11.8% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $617.2M | $581.7M | $622.0M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $746.9M | $720.6M | $758.0M |
| YoY Change | 34.72% | 31.13% | 24.4% |
Cashflow Statement
| Concept | 2023 Q3 | 2023 Q2 | 2022 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | $21.91M | -$54.60M | $6.349M |
| YoY Change | -147.87% | 32.37% | -119.14% |
| Depreciation, Depletion And Amortization | $200.0K | $200.0K | $196.0K |
| YoY Change | 0.0% | 0.0% | -18.33% |
| Cash From Operating Activities | $9.500M | -$44.93M | -$4.976M |
| YoY Change | -130.48% | 27.41% | -77.84% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $500.0K | $771.0K | $151.0K |
| YoY Change | -484.62% | -578.88% | -147.34% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$500.0K | -$771.0K | -$151.0K |
| YoY Change | 284.62% | 378.88% | -52.66% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 2.700M | 18.63M | 220.8M |
| YoY Change | -85.11% | 1420.41% | 12351.49% |
| NET CHANGE | |||
| Cash From Operating Activities | 9.500M | -44.93M | -4.976M |
| Cash From Investing Activities | -500.0K | -771.0K | -151.0K |
| Cash From Financing Activities | 2.700M | 18.63M | 220.8M |
| Net Change In Cash | 11.70M | -27.07M | 215.6M |
| YoY Change | -188.86% | -20.84% | -1126.65% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | $9.500M | -$44.93M | -$4.976M |
| Capital Expenditures | $500.0K | $771.0K | $151.0K |
| Free Cash Flow | $9.000M | -$45.70M | -$5.127M |
| YoY Change | -129.0% | 30.19% | -76.84% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-06-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001559053 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| CY2016Q1 | prta |
Lease Agreement Term Of Contract
LeaseAgreementTermOfContract
|
P7Y9M30D | |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
710406000 | usd |
| CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
0 | usd |
| CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8692000 | usd |
| CY2022Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
0 | usd |
| CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
719098000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1731000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
6277000 | usd |
| CY2022Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
18204000 | usd |
| CY2022Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
2212000 | usd |
| CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
10513000 | usd |
| CY2022Q4 | us-gaap |
Assets Noncurrent
AssetsNoncurrent
|
38937000 | usd |
| CY2022Q4 | us-gaap |
Assets
Assets
|
758035000 | usd |
| CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
9270000 | usd |
| CY2022Q4 | prta |
Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
|
10794000 | usd |
| CY2022Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
11442000 | usd |
| CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
6473000 | usd |
| CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
12168000 | usd |
| CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
50147000 | usd |
| CY2022Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
85293000 | usd |
| CY2023Q2 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
0 | usd |
| CY2023Q2 | prta |
Deferred Shares Share Issued
DeferredSharesShareIssued
|
0 | shares |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-3192000 | usd | |
| us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
8614000 | usd | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-4207000 | usd | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-2416000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-92385000 | usd | |
| us-gaap |
Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
|
819000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-819000 | usd | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
18188000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
41909000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
|
-51295000 | usd | |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
712618000 | usd |
| us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
334000 | usd | |
| prta |
Non Cash Financing Receivable From Option Exercises
NonCashFinancingReceivableFromOptionExercises
|
73000 | usd | |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
659111000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
1352000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
860000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
622042000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
8790000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2540000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-46864000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
607409000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
10100000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
15659000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
2000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-54595000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
581679000 | usd |
| CY2021Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
466042000 | usd |
| CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7660000 | usd |
| CY2022Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
1475000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-41244000 | usd |
| CY2022Q2 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
407299000 | usd |
| CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-934500000 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
659100000 | usd |
| CY2023Q2 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
16116000 | usd |
| CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
8692000 | usd |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risks and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company places its cash equivalents with multiple major and reputable financial institutions. To minimize our risk the Company and its subsidiaries invest pursuant to a Board approved investment policy, which specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. The majority of cash and cash equivalents are invested in liquid money market funds. Cash deposits held with banks may exceed the amount of insurance provided on such deposits. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is primarily conducted in U.S. dollars except for its agreements with contract manufacturers for drug supplies which are denominated in Euros. The Company recorde</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d a loss on</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> foreign currency exchange rate differences of approxim</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ately $238,000 and $72,000 during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2022, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If the Company increases its business activities that require the use of foreign currencies, it may be exposed to losses if the Euro and other such currencies continue to strengthen against the U.S. dollar.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and December 31, 2022, approximately $2.2 million and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of the Company’s property and equipment, net were held in the U.S. and nominal amount were in Ireland.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other late-stage clinical biotechnology companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its drug candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s drug candidates, its right to develop and commercialize its drug candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, and the need to secure and maintain adequate clinical trial management, manufacturing, packaging, labeling, storage, testing, and distribution arrangements with third parties. The Company also relies on third party consultants to assist in managing these third parties and assist with its clinical trial operations and manufacturing. If the Company does not successfully commercialize or partner any of its drug candidates, it will be unable to generate product revenue or achieve profitability. Further, the Company is also subject to broad market risks and uncertainties resulting from recent events, such as the COVID-19 pandemic, the Russian invasion of Ukraine, inflation, rising interest rates, and recession risks, as well as supply chain and labor shortages.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</span></div> | ||
| us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
|
238000 | usd | |
| us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Before Reclassification And Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
|
72000 | usd | |
| CY2023Q2 | prta |
Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
|
6046000 | usd |
| CY2022Q4 | prta |
Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
|
5325000 | usd |
| CY2023Q2 | prta |
Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
|
3268000 | usd |
| CY2022Q4 | prta |
Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
|
1597000 | usd |
| CY2023Q2 | prta |
Receivable From Stock Option Exercises In Transit
ReceivableFromStockOptionExercisesInTransit
|
73000 | usd |
| CY2022Q4 | prta |
Receivable From Stock Option Exercises In Transit
ReceivableFromStockOptionExercisesInTransit
|
62000 | usd |
| CY2023Q2 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
6729000 | usd |
| CY2022Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
1708000 | usd |
| CY2023Q2 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
10553000 | usd |
| CY2022Q4 | us-gaap |
Machinery And Equipment Gross
MachineryAndEquipmentGross
|
9901000 | usd |
| CY2023Q2 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
1498000 | usd |
| CY2022Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
1498000 | usd |
| CY2023Q2 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
1710000 | usd |
| CY2022Q4 | us-gaap |
Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
|
1500000 | usd |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
13761000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
12899000 | usd |
| CY2023Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
11591000 | usd |
| CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
11168000 | usd |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
2170000 | usd |
| CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1731000 | usd |
| CY2023Q2 | us-gaap |
Depreciation
Depreciation
|
200000 | usd |
| us-gaap |
Depreciation
Depreciation
|
400000 | usd | |
| CY2022Q2 | us-gaap |
Depreciation
Depreciation
|
200000 | usd |
| us-gaap |
Depreciation
Depreciation
|
400000 | usd | |
| CY2023Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8279000 | usd |
| CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11060000 | usd |
| CY2023Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
975000 | usd |
| CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
605000 | usd |
| CY2023Q2 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
962000 | usd |
| CY2022Q4 | us-gaap |
Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
|
503000 | usd |
| CY2023Q2 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
10216000 | usd |
| CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
12168000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-54595000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-41244000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-101459000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-77534000 | usd | |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
53121000 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46805000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
52812000 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
46755000 | shares | |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
53121000 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46805000 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
52812000 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
46755000 | shares | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.03 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.88 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.92 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.66 | ||
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.03 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.88 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.92 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.66 | ||
| CY2023Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9951000 | shares |
| CY2022Q2 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10563000 | shares |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
9951000 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10563000 | shares | |
| CY2016Q1 | prta |
Operating Lease Area
OperatingLeaseArea
|
128751 | sqft |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P0Y6M | |
| CY2016Q1 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2023-12-31 | |
| CY2023Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1600000 | usd |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
3200000 | usd | |
| CY2022Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1600000 | usd |
| us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
3200000 | usd | |
| CY2023Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1600000 | usd |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3200000 | usd | |
| CY2022Q2 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1600000 | usd |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3100000 | usd | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0425 | |
| CY2018Q3 | prta |
Operating Leases Sublease Rentals Areaof Sublease Rental
OperatingLeasesSubleaseRentalsAreaofSubleaseRental
|
46641 | sqft |
| CY2023Q2 | us-gaap |
Sublease Income
SubleaseIncome
|
700000 | usd |
| us-gaap |
Sublease Income
SubleaseIncome
|
1500000 | usd | |
| CY2022Q2 | us-gaap |
Sublease Income
SubleaseIncome
|
700000 | usd |
| us-gaap |
Sublease Income
SubleaseIncome
|
1500000 | usd | |
| CY2018Q3 | prta |
Subleaserentals Annual Base Rent Initial Amount
SubleaserentalsAnnualBaseRentInitialAmount
|
2700000 | usd |
| CY2018Q3 | prta |
Operating Leases Sublease Rentals Percent Annual Rent Increase
OperatingLeasesSubleaseRentalsPercentAnnualRentIncrease
|
0.035 | |
| CY2018Q3 | prta |
Operating Leases Sublease Rentals Termof Contract
OperatingLeasesSubleaseRentalsTermofContract
|
P5Y2M12D | |
| CY2018Q3 | prta |
Operating Leases Sublease Rentals Percentof Rental Gain Attributableto Sublandlord
OperatingLeasesSubleaseRentalsPercentofRentalGainAttributabletoSublandlord
|
0.50 | |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
3408000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
|
1460000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
2831000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
|
0 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3052000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
|
0 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3158000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
|
0 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3269000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received Four Years
LessorOperatingLeasePaymentsToBeReceivedFourYears
|
0 | usd |
| CY2023Q2 | prta |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
2523000 | usd |
| CY2023Q2 | prta |
Lessor Operating Lease Payment To Be Received After Year Four
LessorOperatingLeasePaymentToBeReceivedAfterYearFour
|
0 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
18241000 | usd |
| CY2023Q2 | us-gaap |
Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
|
1460000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
48000 | usd |
| CY2023Q2 | prta |
Lessee Operating Lease Liability Lease Not Yet Commenced
LesseeOperatingLeaseLiabilityLeaseNotYetCommenced
|
14745000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
3448000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation
PurchaseObligation
|
15600000 | usd |
| CY2023Q2 | us-gaap |
Contractual Obligation
ContractualObligation
|
400000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation
PurchaseObligation
|
15553000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
|
15395000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
122000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
36000 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
0 | usd |
| CY2023Q2 | us-gaap |
Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
|
0 | usd |
| CY2023Q2 | prta |
Purchase Obligation To Be Paid After Year Four
PurchaseObligationToBePaidAfterYearFour
|
0 | usd |
| CY2023Q2 | prta |
Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
|
15955000 | usd |
| CY2023Q2 | prta |
Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
|
15459000 | usd |
| CY2023Q2 | prta |
Purchase And Contractual Obligation Due In Year One
PurchaseAndContractualObligationDueInYearOne
|
186000 | usd |
| CY2023Q2 | prta |
Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
|
100000 | usd |
| CY2023Q2 | prta |
Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
|
60000 | usd |
| CY2023Q2 | prta |
Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
|
60000 | usd |
| CY2023Q2 | prta |
Purchase And Contractual Obligation Due After Fourth Year
PurchaseAndContractualObligationDueAfterFourthYear
|
90000 | usd |
| CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2023Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
53493467 | shares |
| CY2023Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
53493467 | shares |
| prta |
Numberof Votes
NumberofVotes
|
1 | vote | |
| CY2023Q2 | prta |
Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
|
10000 | shares |
| CY2023Q2 | prta |
Deferred Shares Par Value
DeferredSharesParValue
|
22 | |
| CY2023Q2 | prta |
Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
|
0 | shares |
| CY2023Q2 | prta |
Common Stock Cumulative Number Of Shares Issued
CommonStockCumulativeNumberOfSharesIssued
|
953589 | shares |
| CY2023Q2 | prta |
Proceeds From Issuance Of Common Stock Cumulative Gross Amount
ProceedsFromIssuanceOfCommonStockCumulativeGrossAmount
|
56300000 | usd |
| CY2023Q2 | prta |
Stock Issuance Costs Cumulative Amount
StockIssuanceCostsCumulativeAmount
|
1800000 | usd |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
245200 | shares |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
284250 | shares |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1486371 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2026186 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P4Y | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
3718343 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9928346 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
28.27 | |
| CY2023Q2 | prta |
Share Based Payment Arrangement Estimated Forfeiture Rate
ShareBasedPaymentArrangementEstimatedForfeitureRate
|
0.08 | |
| CY2023Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10100000 | usd |
| CY2022Q2 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
8263000 | usd |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18890000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
15923000 | usd | |
| CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
1800000 | usd |
| CY2022Q2 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
1500000 | usd |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
3400000 | usd | |
| us-gaap |
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
|
3000000 | usd | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.842 | |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.826 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.820 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.822 | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.036 | |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.029 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.042 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.020 | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y11M4D | |
| CY2022Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y10M13D | ||
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
46.10 | |
| CY2022Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
20.30 | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
37.14 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
22.73 | ||
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9479998 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
23.16 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y9M25D | |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
354856000 | usd |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
55.45 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
952402 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
19.11 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
85621 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
36.22 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9928346 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
28.27 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
398931000 | usd |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
9507753 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
27.59 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P6Y11M1D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
388380000 | usd |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
|
5866124 | shares | |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
20.11 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P5Y9M21D | ||
| CY2023Q2 | prta |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
|
282834000 | usd |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-4300000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-7200000 | usd | |
| CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-1300000 | usd |
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-3000000 | usd | |
| CY2023Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2023Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2023Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
